Every patient responded in early tests — now a lymphoma drug pairing gets its big final trial in China

For people whose marginal zone lymphoma — a slow-growing blood cancer — has come back after treatment, options can run thin. China's drug regulators have now cleared a final-stage trial of two pills taken together, mesutoclax and orelabrutinib, for exactly those patients. The pairing already earned breakthrough status in China after earlier study results, shared at a major cancer meeting this year, showed every patient in this group responding to it. The large new trial is the last big test before the treatment could be approved for wider use.